CCMH
NKTR icon

Cornerstone Capital Management Holdings’s Nektar Therapeutics NKTR Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-740
Closed -$187K – 1530
2015
Q4 		$187K Buy
+740
New +$152K ﹤0.01% 1219
2015
Q3 		– Sell
-153
Closed -$29K – 1526
2015
Q2 		$29K Buy
+153
New +$26.3K ﹤0.01% 1380
2015
Q1 		– Sell
-1,287
Closed -$299K – 1412
2014
Q4 		$299K Buy
+1,287
New +$275K ﹤0.01% 1042
2014
Q1 		– Sell
-967
Closed -$164K – 1376
2013
Q4 		$164K Buy
+967
New +$156K ﹤0.01% 1075

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Cornerstone Capital Management Holdings's NKTR Position: Q1 2016 in Review

Cornerstone Capital Management Holdings sold out of Nektar Therapeutics (NKTR) in Q1 2016, closing a stake of 740 shares — an estimated $187K sold.

Cornerstone Capital Management Holdings first reported a position in NKTR in Q4 2013 and held it in 4 quarters. The position peaked at $299K in Q4 2014. 176 funds tracked by Wall St. Rank hold NKTR as of Q1 2016.

  • Cornerstone Capital Management Holdings reported no remaining Nektar Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Cornerstone Capital Management Holdings sold 740 Nektar Therapeutics shares in Q1 2016, an estimated $187K.
  • Cornerstone Capital Management Holdings first reported a position in Nektar Therapeutics in Q4 2013 and held it in 4 quarters.
  • Cornerstone Capital Management Holdings's Nektar Therapeutics position peaked at $299K in Q4 2014.
  • 176 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q1 2016, filed 11 May 2016.